Praxis Precision Medicines, Inc.

Contributing Author

Recent Articles by Praxis Precision Medicines, Inc.

Jan-09	Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PRAX GlobeNewswire
Jan-08	Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments PRAX GlobeNewswire
Jan-06	Praxis Precision Medicines, Inc. Announces Pricing of $575 Million Public Offering PRAX GlobeNewswire
Jan-06	Praxis Precision Medicines, Inc. Announces Proposed Public Offering PRAX GlobeNewswire
Dec-29	Praxis Precision Medicines Announces the FDA Has Granted Breakthrough Therapy Designation for Ulixacaltamide HCl in Essential Tremor PRAX GlobeNewswire
Dec-11	Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026 PRAX GlobeNewswire
Dec-09	Praxis Precision Medicines Announces Alignment with FDA on Simplified and Accelerated Registrational Pathway for Elsunersen in Early Onset SCN2A Developmental and Epileptic Encephalopathy PRAX GlobeNewswire
Dec-08	Praxis AES Wrap-up: Best-in-Class Potential Across Rare Pediatric and Adult Epilepsies PRAX GlobeNewswire
Dec-04	Praxis Precision Medicines Announces Positive Results from EMBOLD Study for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies PRAX GlobeNewswire
Dec-04	Praxis Precision Medicines Announces Positive Pre-NDA Meeting with FDA for Ulixacaltamide in Essential Tremor PRAX GlobeNewswire
Dec-03	Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PRAX GlobeNewswire
Nov-24	Praxis to present latest preclinical and clinical advancements across leading epilepsy portfolio at the 2025 American Epilepsy Society (AES) Annual Meeting PRAX GlobeNewswire
Nov-20	Praxis Precision Medicines to Participate in Upcoming Fireside Chat PRAX GlobeNewswire
Nov-06	Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PRAX GlobeNewswire
Nov-05	Praxis Precision Medicines to Participate in Upcoming Investor Conferences PRAX GlobeNewswire
Nov-05	Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2025 Financial Results PRAX GlobeNewswire
Nov-04	Praxis announces accelerated development path for relutrigine in SCN2A and SCN8A DEE patients following positive FDA feedback PRAX GlobeNewswire
Oct-16	Praxis Precision Medicines, Inc. Announces Pricing of $525 Million Public Offering PRAX GlobeNewswire
Oct-16	Praxis Precision Medicines, Inc. Announces Proposed Public Offering PRAX GlobeNewswire
Oct-16	Praxis Precision Medicines Announces Positive Topline Results from Two Pivotal Phase 3 Studies of Ulixacaltamide HCl in the Essential3 Program for Essential Tremor PRAX GlobeNewswire
Oct-02	Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PRAX GlobeNewswire
Sep-04	Praxis Precision Medicines to Participate in September Investor Conferences PRAX GlobeNewswire
Sep-03	Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PRAX GlobeNewswire
Aug-29	Praxis Precision Medicines to Participate in Upcoming Fireside Chat PRAX GlobeNewswire
Aug-25	Praxis Medicines to Present at 36th International Epilepsy Congress 2025 in Lisbon, Showcasing Latest RADIANT Study Data and Leading Precision Epilepsy Pipeline PRAX GlobeNewswire
Aug-06	Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PRAX GlobeNewswire
Aug-05	Praxis Precision Medicines to Participate in Upcoming Fireside Chat PRAX GlobeNewswire
Aug-04	Praxis Precision Medicines to Participate in Upcoming Fireside Chat PRAX GlobeNewswire
Aug-04	Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2025 Financial Results PRAX GlobeNewswire
Aug-04	Praxis Precision Medicines Announces Positive, Best-in-Disease Topline Results in Patients with Focal Onset Seizures from the RADIANT Study of Vormatrigine PRAX GlobeNewswire
Jul-29	Praxis Precision Medicines to Host Conference Call to Announce Topline Results from the RADIANT Trial and Provide Second Quarter 2025 Financial Results PRAX GlobeNewswire
Jul-17	Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Relutrigine for the Treatment of Seizures Associated with SCN2A and SCN8A Developmental and Epileptic Encephalopathies PRAX GlobeNewswire
Jul-02	Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PRAX GlobeNewswire
Jun-04	Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PRAX GlobeNewswire
May-20	Praxis Precision Medicines to Participate in Upcoming Conferences PRAX GlobeNewswire
May-05	Praxis Precision Medicines Highlights DEE Clinical Program Updates at Virtual Investor Event PRAX GlobeNewswire
May-02	Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PRAX GlobeNewswire
May-02	Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2025 Financial Results PRAX GlobeNewswire

Praxis Precision Medicines, Inc.

Recent Articles by Praxis Precision Medicines, Inc.

Upgrade your FINVIZ experience